Dec 09, 2019 / NTS GMT
Junichi Nezu - Chugai Pharmaceutical Co., Ltd. - General Manager of Research Division
Thank you for attending this meeting today. My name is Nezu, the General Manager of Research Division of Chugai. This is an information meeting on antibody engineering technologies. But before Igawa talks about it, I'd like to briefly explain Chugai's strategy for drug discovery research and the positioning of antibody engineering technologies in the overall strategy.
Please be aware of important reminders. Chugai developed a new midterm business [plan] this year, which includes 5 strategies. Our research division is involved in the strategy 1, value creation, aiming at realizing innovative drug discovery to cure and manage diseases. For that purpose, we developed a basic policy of drug discovery strategy since I became a general manager of that division, and we promote various strategies based on it. The basic policy is the fusion of biology and technology generates innovations in drug discovery. The drug discovery innovation is to create innovative and medically valuable drugs, and that is what we are aiming at in
Chugai Pharmaceutical Co Ltd Antibody Engineering Technologies Information Meeting Transcript
Dec 09, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers